Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KISS1R | Q969F8 | 2/20 | 0.56 |
| ▸ | GHSR | Q92847 | 6/20 | 0.56 |
| ▸ | NPY1R | P25929 | 3/20 | 0.55 |
| ▸ | NPY2R | P49146 | 3/20 | 0.55 |
| ▸ | NPY4R | P50391 | 3/20 | 0.55 |
| ▸ | CCKBR | P32239 | 2/20 | 0.55 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.53 |
| ▸ | MC4R | P32245 | 1/20 | 0.52 |
| ▸ | MC1R | Q01726 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22485386 | 0.84 | CCKBR (0.55) | KISS1RGHSRCCKBR | |
| SCHEMBL31105637 | 0.84 | GHSR (0.60) | KISS1RGHSRC5AR1 | |
| SCHEMBL29527343 | 0.83 | NPY1R (0.70) | KISS1RGHSRNPY1RNPY2RNPY4R | |
| SCHEMBL22339065 | 0.82 | CCKBR (0.63) | KISS1RNPY1RNPY2RNPY4RCCKBR | |
| SCHEMBL9726172 | 0.81 | GHSR (0.66) | GHSR | |
| SCHEMBL30540726 | 0.81 | GHSR (0.62) | GHSR | |
| SCHEMBL30675098 | 0.81 | GHSR (0.66) | GHSR | |
| SCHEMBL9726175 | 0.81 | GHSR (0.66) | GHSR | |
| SCHEMBL28021776 | 0.81 | GHSR (0.66) | GHSR | |
| SCHEMBL29701396 | 0.81 | GHSR (0.55) | GHSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250345289-A1 | NANO-PARTICLES OF MENAQUINONE AND METHODS OF TREATMENT | EPIZON INC (US) | 2025-11-13 | — | — | US | claimed |
| US-20250339386-A1 | VITAMIN K2 FOR USE IN TREATMENT OF CORONARY ARTERY CALCIFICATION | REGION SYDDANMARK (DK) | 2025-11-06 | — | — | US | claimed |
| EP-4590262-A2 | ORAL CARE COMPOSITIONS COMPRISING GERANYLGERANIOL AND METHODS OF USE THEREOF | American River Nutrition, LLC (US) | 2025-07-30 | — | — | EP | claimed |
| EP-4531825-A1 | VITAMIN K2 FOR USE IN TREATMENT OF CORONARY ARTERY CALCIFICATION | Region Syddanmark (DK) | 2025-04-09 | — | — | EP | claimed |
| CN-119300813-A | Vitamin K2 for the treatment of Coronary Artery Calcification (CAC) | 南丹麦大区 | 2025-01-10 | — | — | CN | claimed |
| US-20240307321-A1 | NANO-PARTICLES OF MENAQUINONE AND METHODS OF TREATMENT | Epizon Pharma, Inc. (US) | 2024-09-19 | — | — | US | claimed |
| WO-2024177973-A1 | NANO-PARTICLES OF MENAQUINONE AND METHODS OF TREATMENT | Epizon Pharma, Inc. (US) | 2024-08-29 | — | — | WO | claimed |
| US-20240197589-A1 | ORAL CARE COMPOSITIONS COMPRISING GERANYLGERANIOL AND METHODS OF USE THEREOF | AMERICAN RIVER NUTRITION, LLC (US) | 2024-06-20 | — | — | US | claimed |
| WO-2024064959-A2 | ORAL CARE COMPOSITIONS COMPRISING GERANYLGERANIOL AND METHODS OF USE THEREOF | AMERICAN RIVER NUTRITION, LLC (US) | 2024-03-28 | — | — | WO | claimed |
| WO-2023232643-A1 | VITAMIN K2 FOR USE IN TREATMENT OF CORONARY ARTERY CALCIFICATION | REGION SYDDANMARK (DK) | 2023-12-07 | — | — | WO | claimed |
| WO-2026087629-A1 | LIVE SACCHAROMYCES CEREVISIAE STRAINS FOR THE TREATMENT AND/OR PREVENTION OF BONE-LOSS DISORDERS | LESAFFRE ET COMPAGNIE (FR) | 2026-04-30 | — | — | WO | disclosed |
| EP-4732843-A1 | LIVE SACCHAROMYCES CEREVISIAE STRAINS FOR THE TREATMENT OF BONE-LOSS DISORDERS | Lesaffre et Compagnie (FR) | 2026-04-29 | — | — | EP | disclosed |
| US-20260027147-A1 | EXTRACELLULAR VESICLE-ASO CONSTRUCTS TARGETING CEBP/BETA | LONZA SALES AG (CH) | 2026-01-29 | — | — | US | disclosed |
| US-12527813-B2 | Methods to stabilize and reverse atherosclerotic lesions by sulfated polysaccharides | CALROY HEALTH SCIENCES, LLC (US) | 2026-01-20 | — | — | US | disclosed |
| US-12473248-B2 | Method and intermediate compounds for the preparation of menaquinone MK-7 | VITASYNTH SP. Z.O.O (PL) | 2025-11-18 | — | — | US | disclosed |
| EP-3984533-A2 | COMPOSITIONS COMPRISING CHOLINE AND THEIR USE | Société des Produits Nestlé S.A. (CH) | 2022-04-20 | — | — | EP | disclosed |
| WO-2022072663-A1 | STABILIZED ALKYL NITRITE COMPOSITIONS | EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. (US) | 2022-04-07 | — | — | WO | disclosed |
| WO-2022063956-A1 | STABILIZATION OF VITAMIN A IN A NUTRITIONAL SOLUTION | BAXTER INTERNATIONAL INC. (US) | 2022-03-31 | — | — | WO | disclosed |
| EP-3973949-A1 | STABILIZATION OF VITAMIN A IN A NUTRITIONAL SOLUTION | Baxter International Inc (US) | 2022-03-30 | — | — | EP | disclosed |
| CN-110290775-B | Novel nanoemulsion comprising glycerol in the aqueous phase | 联合利华知识产权控股有限公司 | 2022-03-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240307321-A1 | NANO-PARTICLES OF MENAQUINONE AND METHODS OF TREATMENT | PROC, NDUFS6, NDUFS3 | KISS1R 3244/4885GHSR 4883/4885NPY1R 4797/4885 |
| US-20240197589-A1 | ORAL CARE COMPOSITIONS COMPRISING GERANYLGERANIOL AND METHODS OF USE THEREOF | GGPS1, GLA, GMPS | KISS1R 1534/4885GHSR 592/4885NPY1R 4376/4885 |
| US-12527813-B2 | Methods to stabilize and reverse atherosclerotic lesions by sulfated polysaccharides | RPS4Y1, PF4, PKD1 | KISS1R 989/4885GHSR 3334/4885NPY1R 3007/4885 |
| US-12473248-B2 | Method and intermediate compounds for the preparation of menaquinone MK-7 | SIRT7, NDUFS7, SDHA | KISS1R 1137/4885GHSR 4787/4885NPY1R 4556/4885 |
| US-20260027147-A1 | EXTRACELLULAR VESICLE-ASO CONSTRUCTS TARGETING CEBP/BETA | CEBPZ, OSBP, DIS3 | KISS1R 4835/4885GHSR 4006/4885NPY1R 4503/4885 |
| US-20250345289-A1 | NANO-PARTICLES OF MENAQUINONE AND METHODS OF TREATMENT | PROC, NDUFS6, NDUFS3 | KISS1R 3244/4885GHSR 4883/4885NPY1R 4797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.